Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022

/PRNewswire/ -- Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an update on...

Related Keywords

United States ,Texas ,American ,Greenfire Bio ,Siqing Fu ,Bajit Gill ,Linkedin ,University Of Texas Md Anderson Cancer Center ,Twitter ,Prnewswire Greenfire Bio ,Md Anderson Cancer Center ,World Cancer Research Fund International ,Md Department Of Investigational Cancer Therapeutics ,Facebook ,American Cancer Society ,Cancer Center ,Salt Inducible Kinases ,Poster Presentation ,Gynecologic Cancer ,Investigational Cancer Therapeutics ,Ovarian Cancer ,